Topics

NICE restores parity between Alnylam and Akcea on rare disease

03:45 EDT 9 Jul 2019 | pharmaphorum

NICE has reversed its stance on Alnylam’s gene-silencing drug Onpattro for rare disease hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), backing NHS funding. The decision reverses an earlier rejection of Onpattro (patisiran) in D...

Original Article: NICE restores parity between Alnylam and Akcea on rare disease

NEXT ARTICLE

More From BioPortfolio on "NICE restores parity between Alnylam and Akcea on rare disease"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...